Literature DB >> 17109863

Angiotensin II induces IL-6 expression and the Jak-STAT3 pathway in aortic adventitia of LDL receptor-deficient mice.

Adrian Recinos1, Wanda S LeJeune, Hong Sun, Chang Y Lee, Brian C Tieu, Muping Lu, Tieying Hou, Istvan Boldogh, Ronald G Tilton, Allan R Brasier.   

Abstract

Angiotensin II (A-II), the major effector peptide of the renin angiotensin system potently accelerates progression of atherosclerosis. To investigate its effects on vascular inflammatory mechanisms, we elucidated vascular cytokine expression during early lesion development in A-II-infused atherosclerosis-prone LDLR-/- mice. Male LDLR-/- mice were placed on a "Western" high-fat diet for 4 weeks, followed by sham or A-II infusion for 7 weeks. Equal blood pressures and elevations in serum lipids were seen in both groups. Mice were sacrificed when significant A-II-induced plaque development was first detectable, aortae were explanted and culture media assayed for secreted cytokines. Nine cytokines were significantly induced with interleukin-6 (IL-6) being the most highly secreted. Local IL-6 production was confirmed by in situ mRNA hybridization and immunostaining, where the most abundant IL-6 was found in the aortic adventitia, with lesser production by the medial and intimal layers. Immunofluorescence colocalization showed IL-6 expression by fibroblasts and activated macrophages. Activation of downstream IL-6 signaling mediated by the Jak-STAT3 pathway was demonstrated by inducible phospho-Tyr705-STAT3 formation in the adventitia and endothelium (of IL-6+/+ mice only). These findings define cytokine profiles in the A-II infusion model and demonstrate that IL-6, produced by activated macrophages and fibroblasts in the adventitia, induces the Jak-STAT3 pathway during early A-II-induced atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17109863      PMCID: PMC2196437          DOI: 10.1016/j.atherosclerosis.2006.10.013

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  42 in total

Review 1.  Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant.

Authors:  S Sartore; A Chiavegato; E Faggin; R Franch; M Puato; S Ausoni; P Pauletto
Journal:  Circ Res       Date:  2001-12-07       Impact factor: 17.367

2.  Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice.

Authors:  D Weiss; J J Kools; W R Taylor
Journal:  Circulation       Date:  2001-01-23       Impact factor: 29.690

3.  Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes.

Authors:  S Sugiyama; Y Okada; G K Sukhova; R Virmani; J W Heinecke; P Libby
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

Review 4.  Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-kappaB (NF-kappaB) transcription factor.

Authors:  A R Brasier; M Jamaluddin; Y Han; C Patterson; M S Runge
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

5.  Role of signal transducers and activators of transcription 1 and -3 in inducible regulation of the human angiotensinogen gene by interleukin-6.

Authors:  C T Sherman; A R Brasier
Journal:  Mol Endocrinol       Date:  2001-03

6.  Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress.

Authors:  M E Pueyo; W Gonzalez; A Nicoletti; F Savoie; J F Arnal; J B Michel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-03       Impact factor: 8.311

7.  CC chemokine receptor 2 is required for macrophage infiltration and vascular hypertrophy in angiotensin II-induced hypertension.

Authors:  E Bush; N Maeda; W A Kuziel; T C Dawson; J N Wilcox; H DeLeon; W R Taylor
Journal:  Hypertension       Date:  2000-09       Impact factor: 10.190

8.  Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice.

Authors:  A Daugherty; M W Manning; L A Cassis
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

9.  Angiotensin II increases urokinase-type plasminogen activator expression and induces aneurysm in the abdominal aorta of apolipoprotein E-deficient mice.

Authors:  Y X Wang; B Martin-McNulty; A D Freay; D A Sukovich; M Halks-Miller; W W Li; R Vergona; M E Sullivan; J Morser; W P Dole; G G Deng
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

Review 10.  Role of oxidative stress in atherosclerosis.

Authors:  David Harrison; Kathy K Griendling; Ulf Landmesser; Burkhard Hornig; Helmut Drexler
Journal:  Am J Cardiol       Date:  2003-02-06       Impact factor: 2.778

View more
  50 in total

1.  Aortic adventitial fibroblasts participate in angiotensin-induced vascular wall inflammation and remodeling.

Authors:  Brian C Tieu; Xiaoxi Ju; Chang Lee; Hong Sun; Wanda Lejeune; Adrian Recinos; Allan R Brasier; Ronald G Tilton
Journal:  J Vasc Res       Date:  2010-11-23       Impact factor: 1.934

2.  Tumor necrosis factor-{alpha} suppresses angiotensinogen expression through formation of a p50/p50 homodimer in human renal proximal tubular cells.

Authors:  Ryousuke Satou; Kayoko Miyata; Akemi Katsurada; L Gabriel Navar; Hiroyuki Kobori
Journal:  Am J Physiol Cell Physiol       Date:  2010-06-30       Impact factor: 4.249

3.  Hypertensive urgencies and emergencies: Misconceptions and pitfalls.

Authors:  Fabio Angeli; Gianpaolo Reboldi; Paolo Verdecchia
Journal:  Eur J Intern Med       Date:  2019-11-06       Impact factor: 4.487

4.  Deletion of NF-κB/RelA in Angiotensin II-Sensitive Mesenchymal Cells Blocks Aortic Vascular Inflammation and Abdominal Aortic Aneurysm Formation.

Authors:  Talha Ijaz; Hong Sun; Irina V Pinchuk; Dianna M Milewicz; Ronald G Tilton; Allan R Brasier
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-08-17       Impact factor: 8.311

Review 5.  The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation.

Authors:  Allan R Brasier
Journal:  Cardiovasc Res       Date:  2010-03-03       Impact factor: 10.787

6.  Role of IL-6 in angiotensin II-induced retinal vascular inflammation.

Authors:  Modesto Rojas; Wenbo Zhang; Dexter L Lee; Maritza J Romero; Doan T Nguyen; Mohamed Al-Shabrawey; Nai-Tse Tsai; Gregory I Liou; Michael W Brands; Robert W Caldwell; Ruth B Caldwell
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-15       Impact factor: 4.799

7.  An adventitial IL-6/MCP1 amplification loop accelerates macrophage-mediated vascular inflammation leading to aortic dissection in mice.

Authors:  Brian C Tieu; Chang Lee; Hong Sun; Wanda Lejeune; Adrian Recinos; Xiaoxi Ju; Heidi Spratt; Dong-Chuan Guo; Dianna Milewicz; Ronald G Tilton; Allan R Brasier
Journal:  J Clin Invest       Date:  2009-11-16       Impact factor: 14.808

8.  Interleukin-6-signal transducer and activator of transcription-3 signaling mediates aortic dissections induced by angiotensin II via the T-helper lymphocyte 17-interleukin 17 axis in C57BL/6 mice.

Authors:  Xiaoxi Ju; Talha Ijaz; Hong Sun; Sutapa Ray; Wanda Lejeune; Chang Lee; Adrian Recinos; Dong-Chuan Guo; Dianna M Milewicz; Ronald G Tilton; Allan R Brasier
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-05-16       Impact factor: 8.311

9.  MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II.

Authors:  Hariyadarshi Pannu; Van Tran-Fadulu; Christina L Papke; Steve Scherer; Yaozhong Liu; Caroline Presley; Dongchuan Guo; Anthony L Estrera; Hazim J Safi; Allan R Brasier; G Wesley Vick; A J Marian; C S Raman; L Maximilian Buja; Dianna M Milewicz
Journal:  Hum Mol Genet       Date:  2007-07-31       Impact factor: 6.150

10.  Roles of IL-6-gp130 Signaling in Vascular Inflammation.

Authors:  Tieying Hou; Brian C Tieu; Sutapa Ray; Adrian Recinos Iii; Ruwen Cui; Ronald G Tilton; Allan R Brasier
Journal:  Curr Cardiol Rev       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.